Phase 2 progress strengthens the commercial outlook for PTX-100 in hard-to-treat T-Cell Lymphoma Prescient Therapeutics (ASX: PTX) is progressing through a critical development phase with its lead drug candidate, PTX-100, currently in a global Phase 2 clinical trial for relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL). The drug is believed to be the only GGT-1 inhibitor […]